Basit öğe kaydını göster

dc.contributor.authorOrhan-Sungur, Mukadder
dc.contributor.authorJukar-Rao, S.
dc.contributor.authorMeyer, A.
dc.contributor.authorJalota, L.
dc.contributor.authorWhelan, R. P.
dc.contributor.authorApfel, C. C.
dc.date.accessioned2021-03-06T08:39:28Z
dc.date.available2021-03-06T08:39:28Z
dc.identifier.citationApfel C. C. , Meyer A., Orhan-Sungur M., Jalota L., Whelan R. P. , Jukar-Rao S., "Supplemental intravenous crystalloids for the prevention of postoperative nausea and vomiting: quantitative review", BRITISH JOURNAL OF ANAESTHESIA, cilt.108, ss.893-902, 2012
dc.identifier.issn0007-0912
dc.identifier.othervv_1032021
dc.identifier.otherav_e206e5cd-8683-4012-a0d8-44d9cd5c8524
dc.identifier.urihttp://hdl.handle.net/20.500.12627/148794
dc.identifier.urihttps://doi.org/10.1093/bja/aes138
dc.description.abstractHypovolaemia after overnight fasting is believed to exacerbate postoperative nausea and vomiting (PONV). However, data on the efficacy of supplemental i.v. crystalloids for PONV prophylaxis are conflicting. We performed a literature search using CENTRAL, MEDLINE, EMBASE, CINAHL, and Web of Science. We included prospective randomized controlled trials that reported PONV event rates in patients receiving supplemental i.v. crystalloids or a conservative fluid regimen after elective surgery under general anaesthesia. Studies were evaluated with regard to random sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessment, incomplete outcome data, and selective reporting. We identified 15 trials (n787 crystalloids; n783 conservative fluids). Compared with conservative fluids, i.v. crystalloids reduced the risk of early postoperative nausea (PON) (relative risk 0.73, 95 confidence interval 0.590.89; P0.003), late PON (0.41, 0.220.76; P0.004), and overall PON (0.66, 0.460.95; P0.02). I.V. crystalloids did not reduce the risk of early postoperative vomiting (POV) (0.66, 0.371.16; P0.16) or late POV (0.52, 0.251.11; P0.09), but did reduce overall POV (0.48, 0.290.79; P0.004). I.V. crystalloids did not reduce the risk of early PONV (0.74, 0.491.12; P0.16), but did reduce the risk of late PONV (0.27, 0.130.54; P0.001) and overall PONV (0.59, 0.420.84; P0.003). I.V. crystalloids reduced the need for antiemetic rescue treatment (0.56, 0.450.68; P0.001). In summary, supplemental i.v. crystalloids were associated with a lower incidence of several PONV outcomes. However, a number of PONV outcomes failed to reach statistical significance, perhaps due to the lack of power. Thus, studies sufficiently powered for the less frequent outcomes (e.g. POV) are required.
dc.language.isoeng
dc.subjectCerrahi Tıp Bilimleri
dc.subjectAnesteziyoloji
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectANESTEZİYOLOJİ
dc.titleSupplemental intravenous crystalloids for the prevention of postoperative nausea and vomiting: quantitative review
dc.typeMakale
dc.relation.journalBRITISH JOURNAL OF ANAESTHESIA
dc.contributor.departmentUniversity of California System , ,
dc.identifier.volume108
dc.identifier.startpage893
dc.identifier.endpage902
dc.contributor.firstauthorID2218067


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster